EPISODE · Jul 19, 2017 · 3 MIN
Looking at the CAR-T Landscape As First Approval Nears
from GEN Podcasts
GEN Sounds of Science July 18, 2017Brad Loncar, CEO of Loncar Investments, discusses the outlook for chimeric antigen receptor T cell (CAR-T) cancer therapies as Novartis nears FDA approval for the first such treatment, CTL019. Some other CAR-T therapies have also shown early, yet promising, clinical data. Hosted on Acast. See acast.com/privacy for more information.
Embed this episode
NOW PLAYING
Looking at the CAR-T Landscape As First Approval Nears
0:00
3:43
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of GEN Podcasts?
This episode is 3 minutes long.
When was this GEN Podcasts episode published?
This episode was published on July 19, 2017.
Can I download this GEN Podcasts episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!